Mar 30 2009
RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company's President and Chief Executive Officer, Tod Woolf, Ph.D., will present an industry keynote address at the seventh annual RNAi, MicroRNAs - 2009 - Boston Meeting on Wednesday, April 1, 2009.
Dr. Woolf’s industry keynote address entitled “30 years of targeting RNA: A Retrospective” will provide a historical perspective on the field of targeting RNA. Other speakers include H. Robert Horvitz, Ph.D., recipient of the 2002 Nobel Prize in Physiology or Medicine, and Lasker Prize recipient Paul Zamecnik, MD, whose seminal work on targeting RNA was performed 30 years ago. Dr. Woolf will also review the array of modified oligonucleotide chemistries and configurations that can be used to enhance the therapeutic properties of RNA targeting oligonucleotides.
Dmitry Samarsky, Ph.D., Vice President of Technology Development for RXi Pharmaceuticals, will present the progress made by RXi in developing novel proprietary rxRNA™ compounds, including single-oligo (solo) configurations, as well as novel in vivo delivery approaches, including targeted delivery to migratory macrophages using oral administration.
The seventh annual RNAi, MicroRNAs - 2009 - Boston Meeting organized by GeneExpression Systems™, Inc., is to be held at the Hilton Garden Inn, 420 Trotten Pond Road, Waltham, MA and will not be webcasted. The conference expects experts from academic, business, investment, intellectual property, science media firms and strives to educate the research community with the motto of “Bridging Academia and Industry”.